BioCentury | Mar 26, 2020

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C  Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...
BC Innovations | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets. The study also...
BC Week In Review | Mar 14, 2019
Clinical News

CStone to start Phase I of HDAC6 inhibitor

CStone said China’s National Medical Products Administration (NMPA) approved an IND for a dose-escalation Phase I trial of CS3003 to treat advanced solid tumors and relapsed or refractory multiple myeloma. The trial of the selective...
BC Innovations | Nov 13, 2018
Distillery Therapeutics


INDICATION: Leukemia; multiple myeloma (MM) Cell studies identified a dual HDAC6/proteasome inhibitor that could help treat leukemia and MM. A chemical reaction coupling a N-hydroxybenzamide-based HDAC inhibitor to a tris(oxo-4-phenylbutan-2-ylamino)-based proteasome inhibitor yielded a compound...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Innovations | Sep 26, 2018
Distillery Therapeutics


INDICATION: Leukodystrophy Cell culture, worm and mouse studies suggest inhibiting HDAC6 and other HDACs could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in autophagy, neurogenesis and neuronal...
BC Innovations | Aug 8, 2018
Distillery Therapeutics


INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of analogs...
BC Innovations | Jul 10, 2018
Distillery Therapeutics

Cancer; infectious disease

INDICATION: Acute myelogenous leukemia (AML); Candida In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual JAK-2/HDAC6 inhibitor that could help treat AML and Candida albicans infection. Chemical synthesis of aminopyrimidine analogs linked to...
BioCentury | Apr 13, 2018
Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
Items per page:
1 - 10 of 76